Bimekizumab Efficacy and Safety Through 3 Years in Patients With Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT. J of Skin 2026, 10 (2), s762. https://doi.org/10.25251/g776yf41.